The National Cancer Institute (NCI) awarded a $491,357 Project Grant (CFDA 93.396 - Cancer Biology Research) to Case Western Reserve University's Office of Research Administration Division (doing business as University Hospitals of Cleveland) to study new therapeutic approaches for treating acute myeloid leukemia (AML). The project aims to establish a mechanistic understanding of how hyperactivation of the mTOR pathway can be leveraged to sensitize AML cells to proteasome inhibitor drugs. Key objectives include mapping mitochondrial respiratory lesions, identifying mitochondrial stress vulnerabilities, and determining translation mechanisms that can reverse AML cell quiescence. This research is expected to uncover novel metabolic vulnerabilities in AML that can be targeted pharmacologically. The project period runs from March 15, 2025 through February 28, 2030.
Generated 4/1/25, 2:05 AM